List of Excipients in Branded Drug MYCOBUTIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pfizer Laboratories Div Pfizer Inc	MYCOBUTIN	rifabutin	0013-5301	CELLULOSE, MICROCRYSTALLINE
Pfizer Laboratories Div Pfizer Inc	MYCOBUTIN	rifabutin	0013-5301	FERRIC OXIDE RED
Pfizer Laboratories Div Pfizer Inc	MYCOBUTIN	rifabutin	0013-5301	MAGNESIUM STEARATE
Pfizer Laboratories Div Pfizer Inc	MYCOBUTIN	rifabutin	0013-5301	SILICON DIOXIDE
Pfizer Laboratories Div Pfizer Inc	MYCOBUTIN	rifabutin	0013-5301	SODIUM LAURYL SULFATE
Pfizer Laboratories Div Pfizer Inc	MYCOBUTIN	rifabutin	0013-5301	TITANIUM DIOXIDE

Mycobutin Excipient Strategy and Commercial Opportunities for Rifabutin

Last updated: August 30, 2026

Mycobutin is the branded oral capsule containing rifabutin, a rifamycin antibiotic used primarily for Mycobacterium avium complex, or MAC, disease and selected tuberculosis regimens. The commercial opportunity is no longer centered on the legacy brand. It is centered on differentiated rifabutin formulations that improve exposure, reduce gastrointestinal intolerance, support pediatric or geriatric dosing, and address drug-interaction constraints associated with rifampin.

The strongest development paths are reformulated oral products, pediatric dispersible dosage forms, fixed-dose combination products, and enabling formulations for difficult-to-treat mycobacterial infections. Conventional capsule substitution has limited value because rifabutin is an established generic active ingredient with a relatively mature regulatory profile.

What is Mycobutin and how is rifabutin used?

Mycobutin contains rifabutin, a semisynthetic rifamycin antibiotic. The U.S. product is a 150 mg oral capsule. Its approved uses include prevention of disseminated MAC disease in patients with advanced HIV infection and treatment of MAC disease in combination with other antimycobacterial agents. Rifabutin is also used off-label or in guideline-supported tuberculosis regimens when rifampin is unsuitable because of drug interactions or intolerance.

Rifabutin inhibits bacterial DNA-dependent RNA polymerase. Its clinical value is linked to lower induction of several hepatic drug-metabolizing pathways than rifampin, although clinically relevant interactions remain.

Core product profile

Attribute	Mycobutin and rifabutin
Active ingredient	Rifabutin
Drug class	Rifamycin antimycobacterial
Original dosage form	150 mg hard gelatin capsule
Main approved U.S. use	MAC prophylaxis in advanced HIV infection
Other clinical use	MAC treatment and selected tuberculosis regimens
Administration	Oral
Regulatory category	Small-molecule drug
Biosimilar exposure	None
Main formulation issue	Low aqueous solubility and variable oral exposure
Primary commercial alternatives	Rifampin, rifapentine, azithromycin-based MAC regimens and generic rifabutin

The FDA label identifies rifabutin as a substrate and inducer of drug-metabolizing pathways. The interaction profile is clinically important in HIV treatment, transplant medicine, oncology and patients receiving anticoagulants or immunosuppressants.[1]

What excipients are used in the Mycobutin capsule?

The Mycobutin capsule uses a conventional solid oral formulation. The U.S. prescribing information identifies inactive ingredients including microcrystalline cellulose, corn starch, magnesium stearate, sodium lauryl sulfate, colloidal silicon dioxide and talc. The capsule shell contains gelatin and colorants, including titanium dioxide and approved dyes.[1]

The formulation suggests a conventional immediate-release powder-filled capsule rather than a solubility-enhanced platform. The excipient system supports manufacturability, powder flow and capsule filling, but it does not appear designed to solve rifabutin's central development problem: limited and variable dissolution.

Functional role of the current excipients

Excipient category	Likely function
Microcrystalline cellulose	Diluent and powder structure
Corn starch	Diluent and disintegration support
Magnesium stearate	Lubricant
Sodium lauryl sulfate	Wetting and dispersion aid
Colloidal silicon dioxide	Glidant and moisture-control aid
Talc	Processing aid and anti-adherent
Gelatin	Hard capsule shell
Titanium dioxide and colorants	Capsule identification and appearance

The presence of sodium lauryl sulfate indicates an effort to improve wetting of the hydrophobic drug. That approach is simple and inexpensive, but surfactant concentration, capsule shell compatibility and gastrointestinal tolerability require control.

What formulation problems should an excipient strategy solve?

Rifabutin is a lipophilic compound with limited aqueous solubility. Its absorption can vary with formulation, food intake, gastrointestinal conditions and concurrent medicines. A new excipient strategy should target four measurable outcomes:

1. Faster and more complete dissolution.
2. Lower pharmacokinetic variability.
3. Reduced food effect or improved administration flexibility.
4. Lower total dose burden where exposure can be maintained.

A formulation that increases exposure without controlling peak concentrations could increase adverse reactions, including uveitis, neutropenia, leukopenia, thrombocytopenia, gastrointestinal effects and orange-red discoloration of body fluids. The development target should therefore be controlled exposure rather than maximum exposure.

Technical screening priorities

Excipient screening should examine:

• Apparent solubility across physiologic pH.
• Dissolution in biorelevant media.
• Supersaturation and precipitation after dispersion.
• Drug-excipient chemical compatibility.
• Rifabutin degradation under light, oxygen and humidity.
• Capsule shell migration and cross-linking.
• Food-effect performance.
• Interaction with antiretroviral and antimycobacterial co-therapies.
• Stability under high-temperature and high-humidity conditions.

Rifabutin is strongly colored. Color migration, capsule staining and visual uniformity are practical development issues. Excipient systems that produce a stable, low-dust blend are preferable for manufacturing and patient handling.

Which excipient platforms offer the strongest commercial opportunity?

Amorphous solid dispersions

An amorphous solid dispersion using a polymer such as copovidone, hypromellose acetate succinate or selected cellulose derivatives could increase apparent solubility and dissolution. The commercial value would depend on maintaining the amorphous state during storage.

This platform is suitable for a capsule or tablet and could support a lower-strength product. Its main risks are recrystallization, hygroscopicity and a larger unit dose caused by polymer loading.

Lipid-based formulations

Self-emulsifying or self-microemulsifying drug-delivery systems could improve dissolution of rifabutin through solubilization in a lipid phase. Candidate excipients may include medium-chain triglycerides, mono- and diglycerides, polyethylene glycol-based surfactants and co-solvents.

Lipid systems are commercially attractive if they reduce food dependence or improve exposure in patients with gastrointestinal disease. The main constraints are capsule compatibility, liquid-fill manufacturing, oxidation control and gastrointestinal tolerability.

Nanocrystal or nanosuspension products

Rifabutin nanocrystals could increase surface area and accelerate dissolution without requiring a large polymer load. The product could be developed as a capsule, tablet, oral suspension or sachet.

This approach offers a route to pediatric and geriatric products. It also creates stronger formulation differentiation than a conventional capsule. The regulatory burden is higher because particle-size distribution, aggregation, redispersibility and process reproducibility become critical quality attributes.

Cyclodextrin and inclusion-complex systems

Cyclodextrin complexes may improve apparent aqueous solubility. Their commercial value is less certain because high excipient levels can increase dose volume and cost. The approach is more suitable for a liquid or dispersible product than for a compact 150 mg capsule unless complexation efficiency is high.

Lipid-polymer hybrid systems

A hybrid formulation combining a lipid vehicle with a precipitation-inhibiting polymer could provide more durable supersaturation than a simple surfactant system. It may be appropriate for a premium reformulation, but manufacturing complexity and intellectual-property crowding are higher.

What formulations are protected by Mycobutin patents?

The original Mycobutin product was developed decades ago, and the core composition-of-matter protection for rifabutin has expired. The conventional 150 mg capsule does not provide a strong basis for new exclusivity.

Commercially relevant protection would need to come from a later patent family covering a specific formulation, process, dosage regimen or combination. Potential claim categories include:

• Rifabutin amorphous dispersions.
• Nanoparticle or nanocrystal compositions.
• Self-emulsifying drug-delivery systems.
• Pediatric dispersible or taste-masked products.
• Fixed-dose combinations with companion antimycobacterial agents.
• Stabilized rifabutin compositions.
• Manufacturing processes that produce a defined solid-state form.
• Drug-interaction-adjusted regimens involving rifabutin and antiretroviral therapy.

A patent must claim a technically defined composition or process. Broad claims to rifabutin with ordinary fillers, lubricants or disintegrants would face substantial validity and obviousness risk.

How strong is the patent estate for Mycobutin?

The legacy Mycobutin estate is commercially weak compared with a recently launched branded medicine. Rifabutin's active ingredient is old, the standard capsule is conventional and generic competition exists. The stronger opportunity is to build a new formulation estate with:

• Defined particle size or solid state.
• Quantified dissolution performance.
• Narrow excipient ranges.
• Stability data.
• Comparative pharmacokinetic results.
• Clinical evidence supporting reduced interactions or improved tolerability.

A formulation patent supported only by routine excipient substitution would have limited defensive value. A patent linked to a clinically meaningful reduction in rifabutin dose, food effect or interaction burden would be stronger.

When does Mycobutin lose exclusivity?

Mycobutin's original regulatory and patent exclusivity periods have expired. The product is not a biologic and does not receive biosimilar exclusivity. Generic rifabutin capsules can be approved through the abbreviated new drug application pathway if they demonstrate pharmaceutical equivalence and bioequivalence.

The relevant commercial protection questions are therefore:

Protection type	Mycobutin position
Composition-of-matter patent	Expired
Original new-drug exclusivity	Expired
Orphan exclusivity	Not the principal protection for the product
Biosimilar exclusivity	Not applicable
Generic pathway	ANDA pathway available
New formulation exclusivity	Available only through a newly approved differentiated product
Pediatric exclusivity	Product-specific and not a continuing legacy barrier

The FDA Orange Book should be used to confirm current patent and exclusivity entries for NDA 020780 and any listed generic products.[2]

What is the Orange Book status of Mycobutin?

Mycobutin is associated with NDA 020780 in the FDA regulatory database. The Orange Book records approved drug products, therapeutic equivalence information and, where applicable, listed patents and exclusivity.[2]

For commercial diligence, the key issue is whether any current patent listing remains attached to the reference product. A legacy capsule without active listed patents presents a lower Paragraph IV barrier than a product with active formulation or method-of-use listings.

Any new rifabutin product would require a separate regulatory strategy. A reformulated product with a new dosage form, strength or clinical benefit could be submitted as a 505(b)(2) application if it relies partly on FDA findings for rifabutin while providing bridging data for the new formulation. A fully substitutable capsule would generally be less differentiated.

Which companies are challenging Mycobutin and selling rifabutin?

The competitive field includes generic manufacturers and suppliers of alternative rifamycins. Generic rifabutin capsules have reduced the strategic value of the Mycobutin brand. The relevant competition is not limited to named rifabutin manufacturers because physicians may substitute rifampin or rifapentine depending on indication and drug-interaction requirements.

The most relevant competitor groups are:

• Generic rifabutin capsule manufacturers.
• Rifampin suppliers.
• Rifapentine suppliers.
• MAC regimen manufacturers supplying macrolides and companion agents.
• Developers of long-acting antimycobacterial delivery systems.
• Contract manufacturers producing low-volume antibiotic products.

Supplier continuity is a meaningful commercial variable. Rifabutin is a specialized product with lower volume than many antibiotics. A manufacturer offering reliable supply, pediatric strengths or hospital-focused packaging may compete effectively even without a major formulation advance.

What Paragraph IV risks exist for a new rifabutin formulation?

A new formulation could face Paragraph IV litigation if an ANDA applicant seeks approval before expiration of listed formulation patents. The risk depends on the Orange Book listings for the new reference product, not the expired legacy Mycobutin capsule.

Key risks include:

• Obviousness challenges based on known solubility-enhancement techniques.
• Lack of unexpected results from routine surfactant or polymer selection.
• Design-around using a different polymer, lipid system or particle-size range.
• Narrow claim scope caused by prior-art formulation patents.
• Difficulty listing method-of-use claims for broad infectious-disease indications.
• Failure to establish that the formulation produces a clinically meaningful benefit.

A 505(b)(2) product may face patent certification requirements and potential litigation if it references a listed drug. A product positioned as a non-substitutable dosage form, such as a pediatric suspension, may reduce direct capsule substitution but will not eliminate patent challenges.

What FDA regulatory pathway is best for an improved rifabutin product?

A 505(b)(2) pathway is the most commercially plausible route for a reformulated rifabutin product. The applicant could rely on FDA's prior findings for rifabutin while submitting new chemistry, manufacturing and controls data, pharmacokinetic studies, stability data and, where needed, clinical efficacy or safety evidence.[3]

Candidate products

Product concept	Likely pathway	Commercial rationale
Improved 150 mg capsule	505(b)(2) or ANDA, depending on formulation and claims	Easier prescribing transition but limited differentiation
75 mg or 100 mg capsule	505(b)(2)	Dose flexibility and pediatric or interaction-management use
Pediatric dispersible tablet	505(b)(2)	Addresses swallowing and dosing limitations
Oral suspension	505(b)(2)	Pediatric, geriatric and feeding-tube administration
Fixed-dose combination	505(b)(2) or full combination-product route	Simplifies multidrug therapy
Nanocrystal capsule	505(b)(2)	Solubility and exposure differentiation
Long-acting injectable	New drug development	High technical and clinical cost, potentially high differentiation

An ANDA would be appropriate for a product that is pharmaceutically equivalent to the reference capsule. That strategy can reduce development cost but offers little protection beyond manufacturing efficiency, supply reliability and pricing.

What commercial opportunities exist for rifabutin excipient innovation?

Pediatric and geriatric delivery

A dispersible tablet, mini-tablet or oral suspension could address patients who cannot swallow a 150 mg capsule. Pediatric tuberculosis and nontuberculous mycobacterial disease are important use cases, but dosing must be tied to weight, co-medications and clinical guidance.

Taste masking is difficult because rifabutin is intensely colored and may have an unpleasant taste. Polymer coating, ion-exchange resins and multiparticulate systems could reduce direct contact with taste receptors.

HIV drug-interaction management

Rifabutin is used when rifampin is unsuitable because rifampin has stronger enzyme-inducing effects. A formulation that provides predictable exposure at a lower dose could support use with complex antiretroviral regimens. The commercial proposition would require clinical interaction studies, not only dissolution data.

Tuberculosis combination therapy

Rifabutin could be incorporated into fixed-dose or co-packaged regimens with companion tuberculosis drugs. The technical obstacles include different dose ratios, chemical stability, dissolution behavior and regulatory requirements for combination products.

A fixed-dose combination may reduce adherence burden but could limit dosing flexibility when renal function, body weight or drug interactions require individual adjustment.

Hospital and specialty supply

A reliable rifabutin product can have value in hospitals, HIV clinics, transplant centers and infectious-disease pharmacies. Supply continuity, short lead times and hospital contracts may provide a more realistic commercial advantage than consumer branding.

How does Mycobutin compare with rifampin and rifapentine?

Factor	Rifabutin	Rifampin	Rifapentine
Drug-interaction burden	Lower than rifampin in some settings, but still significant	High enzyme induction	Significant, with regimen-specific considerations
Main role	MAC and selected TB regimens	Broad TB use and other infections	Selected TB regimens
Legacy formulation opportunity	Moderate	Low to moderate	Moderate
Pediatric product opportunity	High	More established	Regimen-dependent
Solubility/formulation challenge	Meaningful	Meaningful	Meaningful
Premium pricing potential	Specialty-driven	Limited in generic markets	Depends on supply and indication
Best differentiation route	Interaction-aware and pediatric formulations	Combination and adherence products	Long-acting or regimen-specific products

Rifabutin's commercial niche is based on clinical selection rather than broad antibiotic volume. That supports premium positioning only where the product solves a treatment constraint.

What manufacturing and intellectual-property barriers apply?

The API is not the only manufacturing risk. Rifabutin products require control of:

• Blend uniformity at relatively low dose levels.
• Powder flow and segregation.
• Light and humidity exposure.
• Capsule-fill weight variation.
• Color consistency.
• Residual solvents in lipid or amorphous systems.
• Particle-size distribution for nanocrystal products.
• Polymorphic or amorphous-state stability.
• Cleaning validation for a strongly colored antibiotic.

A conventional capsule has a low manufacturing barrier. A lipid, amorphous or nanocrystal product can create process know-how that is difficult to reproduce, even if patent claims are narrow.

What licensing deals could support a rifabutin product?

The most practical licensing targets are:

1. A formulation technology provider with lipid, amorphous-dispersion or nanocrystal capabilities.
2. A regional infectious-disease company with HIV and tuberculosis distribution.
3. A generic manufacturer with established rifabutin API sourcing.
4. A contract development and manufacturing organization with low-volume antibiotic capacity.
5. A public-health or global-access partner for pediatric and tuberculosis products.

The legacy Mycobutin brand itself is unlikely to justify a major licensing premium. Value would come from rights to a differentiated formulation, regulatory dossier, manufacturing process or regional supply network.

Key Takeaways

• Mycobutin is the legacy 150 mg rifabutin capsule associated with NDA 020780.
• Its original exclusivity has expired, and conventional generic competition limits capsule-level pricing power.
• The current excipient system is conventional and does not fully address rifabutin's solubility and exposure variability.
• The strongest formulation opportunities are amorphous dispersions, lipid systems, nanocrystals and pediatric dispersible products.
• A 505(b)(2) application is the leading regulatory pathway for a clinically differentiated reformulation.
• Pediatric delivery, HIV drug-interaction management and specialty hospital supply are the most credible commercial niches.
• New patents should focus on defined solid-state, particle-size, excipient-range, stability or pharmacokinetic advantages.
• Biosimilar risk does not apply because rifabutin is a small-molecule drug.
• Manufacturing know-how may provide more durable protection than a broad excipient patent.
• A new product must demonstrate a clinical or pharmacokinetic benefit to avoid competing solely on generic price.

FAQs

Can rifabutin be reformulated as an oral suspension?

Yes. An oral suspension could target pediatric patients, patients with swallowing difficulties and feeding-tube administration. The main development issues are sedimentation, redispersibility, dose uniformity, taste masking, color control and chemical stability.

Would a rifabutin fixed-dose combination be commercially attractive?

It could be attractive for tuberculosis or MAC treatment if the dose ratios match clinical practice. The main barriers are inflexible dosing, separate stability profiles and the need to demonstrate compatibility and bioequivalence or clinical performance for the combination.

Is a lower-dose rifabutin capsule commercially viable?

Potentially. A 75 mg or 100 mg capsule could support weight-based dosing and interaction management. Its value would depend on pharmacokinetic evidence showing reliable exposure and on whether the product gains regulatory protection beyond ordinary generic substitution.

Does rifabutin have biosimilar competition?

No. Rifabutin is a chemically synthesized small molecule. Competition occurs through generic drug applications, not biosimilar applications.

What is the most defensible rifabutin patent strategy?

The strongest strategy would combine a defined formulation platform with comparative pharmacokinetic or clinical data. Claims directed only to ordinary fillers, lubricants or surfactants would likely provide weak protection unless the formulation produces an unexpected and reproducible result.

References

1. U.S. Food and Drug Administration. (n.d.). Mycobutin (rifabutin) capsules prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). FDA.

4. World Health Organization. (2022). WHO consolidated guidelines on tuberculosis: Module 4, treatment: Drug-resistant tuberculosis treatment. World Health Organization.

5. Centers for Disease Control and Prevention. (2024). Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: Mycobacterium avium complex disease. U.S. Department of Health and Human Services.